Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 17/20 | 0.41 |
| ▸ | KCNJ11 | Q14654 | 17/20 | 0.41 |
| ▸ | ABCC8 | Q09428 | 13/20 | 0.41 |
| ▸ | KCNJ8 | Q15842 | 13/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7548195 | 0.86 | PTGS2 (0.40) | MAOB | |
| SCHEMBL6995497 | 0.80 | PTGS1 (0.41) | PARP1 | |
| SCHEMBL29822762 | 0.79 | ALDH1A1 (0.39) | — | |
| SCHEMBL29822613 | 0.77 | NOTUM (0.36) | MAOB | |
| SCHEMBL6995502 | 0.76 | PTGS1 (0.40) | — | |
| SCHEMBL979154 | 0.75 | CYP2C19 (0.41) | MAOB | |
| SCHEMBL29822654 | 0.73 | LMNA (0.40) | MAOB | |
| SCHEMBL29822805 | 0.70 | BACE1 (0.49) | — | |
| SCHEMBL12263267 | 0.70 | TSHR (0.40) | — | |
| SCHEMBL4352639 | 0.68 | PARP1 (0.42) | ABCC9KCNJ11ABCC8KCNJ8PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603901-B1 | TETRAHYDROPYRAN COMPOUNDS AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2008-10-15 | — | — | EP | disclosed |
| US-7393858-B2 | Tetrahydropyran compounds as tachykinin antagonists | MERCK SHARP & DOHME LTD. (GB) | 2008-07-01 | — | — | US | disclosed |
| US-20060172999-A1 | Tetrahydropyran compounds as tachykinin antagonists | MERCK SHARP & DOHME LTD. (GB) | 2006-08-03 | — | — | US | disclosed |
| EP-1603901-A1 | TETRAHYDROPYRAN COMPOUNDS AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004078750-A1 | TETRAHYDROPYRAN COMPOUNDS AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060172999-A1 | Tetrahydropyran compounds as tachykinin antagonists | NPSR1, NPY1R, OPRL1 | ABCC9 643/4885KCNJ11 394/4885ABCC8 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.